Sam Brusco, Associate Editor09.12.22
Edwards Lifesciences launched its Sapien 3 Ultra Resilia valve incorporating its breakthrough Resilia tissue technology with the Sapien 3 Ultra transcatheter aortic heart valve. The launch followed recent U.S. Food and Drug Administration (FDA) approval.
Resilia is bovine pericardial tissue treated with advanced anti-calcification tech and is the platform for Edwards' new class of valves, including the next generation SAPIEN X4 valve, currently in clinical trials. Resilia tissue, according to Edwards, boosts calcium blocking properties and dry tissue packaging conditions. It has demonstrated freedom from structural valve deterioration at five years.
"The SAPIEN 3 Ultra RESILIA valve builds on Edwards' 40 years of leadership in tissue technology by combining advancements in tissue science with the industry leading SAPIEN 3 Ultra valve to offer the only dry storage transcatheter heart valve on the U.S. market today," Larry Wood, corporate VP, transcatheter aortic valve replacement, told the press. "The RESILIA tissue's anti-calcification technology addresses one of the primary causes of reintervention following heart valve replacement. The SAPIEN 3 Ultra RESILIA valve is a prime example of Edwards' continued focus on innovating to meet the current and future needs of patients to help them live longer, healthier and more productive lives."
Sapien 3 Ultra Resilia will release in the U.S. on a limited basis in Q4 2022.
Resilia is bovine pericardial tissue treated with advanced anti-calcification tech and is the platform for Edwards' new class of valves, including the next generation SAPIEN X4 valve, currently in clinical trials. Resilia tissue, according to Edwards, boosts calcium blocking properties and dry tissue packaging conditions. It has demonstrated freedom from structural valve deterioration at five years.
"The SAPIEN 3 Ultra RESILIA valve builds on Edwards' 40 years of leadership in tissue technology by combining advancements in tissue science with the industry leading SAPIEN 3 Ultra valve to offer the only dry storage transcatheter heart valve on the U.S. market today," Larry Wood, corporate VP, transcatheter aortic valve replacement, told the press. "The RESILIA tissue's anti-calcification technology addresses one of the primary causes of reintervention following heart valve replacement. The SAPIEN 3 Ultra RESILIA valve is a prime example of Edwards' continued focus on innovating to meet the current and future needs of patients to help them live longer, healthier and more productive lives."
Sapien 3 Ultra Resilia will release in the U.S. on a limited basis in Q4 2022.